Metadata
Author: Literature
Data
English[en]
About 10–15% of pts with advanced-stage disease may benefit from interleukin 2 and/or interferon α (IFN-α).
Spanish[es]
Entre 10 y 15% de los pacientes con enfermedad avanzada se benefician con interleucina-2 y/o interferón α (IFN-α).